



## Clinical trial results:

### A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)

#### Summary

EudraCT number	2017-005028-11
Trial protocol	GB CZ DE AT HU PL BE ES GR NL HR IT RO
Global end of trial date	01 April 2022

#### Results information

Result version number	v1
This version publication date	16 April 2023
First version publication date	16 April 2023

#### Trial information

##### Trial identification

Sponsor protocol code	I4V-MC-JAIM
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03843125
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Number: 16832

Notes:

#### Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 8772854559,

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 April 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	01 April 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 September 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 192
Country: Number of subjects enrolled	Czechia: 28
Country: Number of subjects enrolled	Russian Federation: 57
Country: Number of subjects enrolled	Greece: 15
Country: Number of subjects enrolled	Korea, Republic of: 18
Country: Number of subjects enrolled	Netherlands: 2
Country: Number of subjects enrolled	Austria: 2
Country: Number of subjects enrolled	China: 51
Country: Number of subjects enrolled	Poland: 79
Country: Number of subjects enrolled	Brazil: 60
Country: Number of subjects enrolled	France: 2
Country: Number of subjects enrolled	Serbia: 43
Country: Number of subjects enrolled	Chile: 27
Country: Number of subjects enrolled	Croatia: 6
Country: Number of subjects enrolled	Colombia: 39
Country: Number of subjects enrolled	Argentina: 73
Country: Number of subjects enrolled	Romania: 24
Country: Number of subjects enrolled	Hungary: 39
Country: Number of subjects enrolled	Japan: 24

Country: Number of subjects enrolled	Philippines: 33
Country: Number of subjects enrolled	United Kingdom: 10
Country: Number of subjects enrolled	Switzerland: 2
Country: Number of subjects enrolled	India: 65
Country: Number of subjects enrolled	Spain: 21
Country: Number of subjects enrolled	Belgium: 3
Country: Number of subjects enrolled	Taiwan: 30
Country: Number of subjects enrolled	Italy: 4
Country: Number of subjects enrolled	Mexico: 112
Country: Number of subjects enrolled	South Africa: 34
Country: Number of subjects enrolled	Israel: 6
Country: Number of subjects enrolled	Australia: 17
Country: Number of subjects enrolled	Germany: 29
Worldwide total number of subjects	1147
EEA total number of subjects	254

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1088
From 65 to 84 years	59
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Participants who completed originating study [I4V-MC-JAHZ (NCT03616912) or Study I4V-MC-JAIA (NCT03616964)] were enrolled in this study. Safety population included all participants who received at least one dose of study drug and who did not discontinue from the study for the reason 'Lost to Follow-up' at the first post-baseline visit.

### Pre-assignment

Screening details:

Participants who were randomized to placebo during originating Study I4V-MC-JAHZ (NCT03616912) or Study I4V-MC-JAIA (NCT03616964) were randomized 1:1 to receive baricitinib 4-milligram (mg) or baricitinib 2-mg once daily (QD), administered orally.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	2 milligrams (mg) Baricitinib

Arm description:

Participants received one 2 mg Baricitinib tablet and one placebo tablet matching 4 mg Baricitinib administered orally every day (QD).

Arm type	Experimental
Investigational medicinal product name	Baricitinib
Investigational medicinal product code	
Other name	LY3009104
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received one 2 mg Baricitinib tablet administered orally every day (QD).

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received one placebo tablet matching 4 mg Baricitinib administered orally QD.

<b>Arm title</b>	4 mg Baricitinib
------------------	------------------

Arm description:

Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally QD.

Arm type	Experimental
Investigational medicinal product name	Baricitinib
Investigational medicinal product code	
Other name	LY3009104
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:	
Participants received one 2 mg Baricitinib tablet administered orally QD.	
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Participants received one placebo tablet matching 2 mg Baricitinib administered orally QD.	
<b>Arm title</b>	Placebo to 2 mg Baricitinib
Arm description:	
Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 2 mg Baricitinib administered orally QD.	
Arm type	Experimental
Investigational medicinal product name	Baricitinib
Investigational medicinal product code	
Other name	LY3009104
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Participants received one 2 mg Baricitinib tablet administered orally QD.	
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Participants received one placebo tablet matching 4 mg Baricitinib administered orally QD.	
<b>Arm title</b>	Placebo to 4 mg Baricitinib
Arm description:	
Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 4 mg Baricitinib administered orally QD.	
Arm type	Experimental
Investigational medicinal product name	Baricitinib
Investigational medicinal product code	
Other name	LY3009104
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Participants received one 4 mg Baricitinib tablet administered orally QD.	
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Participants received one placebo tablet matching 2 mg Baricitinib administered orally QD.	

<b>Number of subjects in period 1</b>	<b>2 milligrams (mg) Baricitinib</b>	<b>4 mg Baricitinib</b>	<b>Placebo to 2 mg Baricitinib</b>
Started	388	379	189
Safety Population	388	378	189
Completed	0	0	0
Not completed	388	379	189
Adverse event, serious fatal	-	6	2
Consent withdrawn by subject	23	12	6
Adverse event, non-fatal	17	13	5
Due to Epidemic/Pandemic	1	-	-
Unknown	12	14	3
Study Terminated by Sponsor	318	318	163
Lost to follow-up	3	4	-
Missing data	-	1	1
Lack of efficacy	14	11	9

<b>Number of subjects in period 1</b>	<b>Placebo to 4 mg Baricitinib</b>
Started	191
Safety Population	191
Completed	0
Not completed	191
Adverse event, serious fatal	-
Consent withdrawn by subject	9
Adverse event, non-fatal	9
Due to Epidemic/Pandemic	-
Unknown	4
Study Terminated by Sponsor	163
Lost to follow-up	2
Missing data	-
Lack of efficacy	4

## Baseline characteristics

### Reporting groups

Reporting group title	2 milligrams (mg) Baricitinib
Reporting group description: Participants received one 2 mg Baricitinib tablet and one placebo tablet matching 4 mg Baricitinib administered orally every day (QD).	
Reporting group title	4 mg Baricitinib
Reporting group description: Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally QD.	
Reporting group title	Placebo to 2 mg Baricitinib
Reporting group description: Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 2 mg Baricitinib administered orally QD.	
Reporting group title	Placebo to 4 mg Baricitinib
Reporting group description: Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 4 mg Baricitinib administered orally QD.	

Reporting group values	2 milligrams (mg) Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib
Number of subjects	388	379	189
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	43.8	43.8	43.8
standard deviation	± 12.68	± 12.03	± 11.85
Gender categorical			
Units: Subjects			
Female	361	357	181
Male	27	22	8
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	21	16	13
Asian	79	77	44
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	32	36	19
White	249	241	109
More than one race	3	2	2
Unknown or Not Reported	4	7	2
Region of Enrollment			
Units: Subjects			
United States	66	68	28
Czechia	7	9	7
Russia	19	16	11
Greece	8	4	0
South Korea	7	7	2

Netherlands	1	1	0
Austria	1	1	0
China	17	18	10
Poland	27	28	11
Brazil	17	19	14
France	0	1	0
Serbia	18	15	3
Chile	12	7	4
Croatia	3	1	1
Colombia	11	13	8
Argentina	21	23	13
Romania	11	6	3
Hungary	16	13	5
Japan	6	9	4
Philippines	13	8	5
United Kingdom	3	3	3
Switzerland	0	0	2
India	20	20	13
Spain	3	9	6
Belgium	1	1	1
Taiwan	8	10	5
Italy	2	0	1
Mexico	40	40	15
South Africa	13	9	6
Israel	3	3	0
Australia	5	6	4
Germany	9	11	4

<b>Reporting group values</b>	Placebo to 4 mg Baricitinib	Total	
Number of subjects	191	1147	
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	43.5		
standard deviation	± 13.22	-	
Gender categorical			
Units: Subjects			
Female	176	1075	
Male	15	72	
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	11	61	
Asian	41	241	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	19	106	
White	115	714	
More than one race	2	9	
Unknown or Not Reported	3	16	



Region of Enrollment			
Units: Subjects			
United States	30	192	
Czechia	5	28	
Russia	11	57	
Greece	3	15	
South Korea	2	18	
Netherlands	0	2	
Austria	0	2	
China	6	51	
Poland	13	79	
Brazil	10	60	
France	1	2	
Serbia	7	43	
Chile	4	27	
Croatia	1	6	
Colombia	7	39	
Argentina	16	73	
Romania	4	24	
Hungary	5	39	
Japan	5	24	
Philippines	7	33	
United Kingdom	1	10	
Switzerland	0	2	
India	12	65	
Spain	3	21	
Belgium	0	3	
Taiwan	7	30	
Italy	1	4	
Mexico	17	112	
South Africa	6	34	
Israel	0	6	
Australia	2	17	
Germany	5	29	

## End points

### End points reporting groups

Reporting group title	2 milligrams (mg) Baricitinib
Reporting group description: Participants received one 2 mg Baricitinib tablet and one placebo tablet matching 4 mg Baricitinib administered orally every day (QD).	
Reporting group title	4 mg Baricitinib
Reporting group description: Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally QD.	
Reporting group title	Placebo to 2 mg Baricitinib
Reporting group description: Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 2 mg Baricitinib administered orally QD.	
Reporting group title	Placebo to 4 mg Baricitinib
Reporting group description: Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 4 mg Baricitinib administered orally QD.	

### Primary: Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs)

End point title	Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs) <sup>[1]</sup>
End point description: Percentage of participants with TEAEs. A treatment-emergent AE (TEAE) is defined as an event that first occurred or worsened in severity after the first dose of study treatment in Study JAIM and on or prior to the last visit date during the analysis period. The analysis period is defined as the treatment period plus up to 30 days off-drug follow-up time. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module. Analysis population description (APD): All participants who received at least one dose of study drug.	
End point type	Primary
End point timeframe: Week 134	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No inferential statistics were planned for this endpoint.	

End point values	2 milligrams (mg) Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib	Placebo to 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	388	378	189	191
Units: Percentage of Participants				
number (not applicable)	61.9	68.8	65.1	64.4

### Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Participants with Adverse Events of Special Interest (AESIs)

End point title	Percentage of Participants with Adverse Events of Special Interest (AESIs) <sup>[2]</sup>
-----------------	---

End point description:

Percentage of Participants with AESIs. AESI consisted of infections, positively adjudicated arterial thromboembolic events (ATE), positively adjudicated venous thromboembolic events (VTE), positively adjudicated major adverse cardiovascular events (MACE), other positively adjudicated cardiovascular events, death, anaphylactic reactions, hypersensitivity, angioedema, and malignancies.

APD: All participants who received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Week 134

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No inferential statistics were planned for this endpoint.

End point values	2 milligrams (mg) Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib	Placebo to 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	388	378	189	191
Units: Percentage of participants				
number (not applicable)				
Infections	38.4	42.1	36.5	35.1
Positively adjudicated ATE	0.3	0.8	0.5	0.5
Positively adjudicated VTE	0.3	1.1	0.5	0.5
Positively adjudicated MACE	0.3	0.8	0.5	0.5
Other positively adjudicated cardiovascular events	0.3	0.8	0	0.5
Death	0	1.6	1.1	0
Anaphylactic reactions	3.6	4.2	5.8	3.1
Hypersensitivity	3.6	4.2	5.8	3.1
Angioedema	1.3	0.8	1.6	0
Malignancies	0.5	0.3	0	0

### Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Participants with Serious Adverse Events (SAEs)

End point title	Percentage of Participants with Serious Adverse Events
-----------------	--

End point description:

Percentage of participants with SAEs. An SAE is any AE from this study that results in one of the following outcomes: Death; Initial or prolonged inpatient hospitalization; A life-threatening experience (that is, immediate risk of dying); Persistent or significant disability/incapacity; Congenital anomaly/birth defect; Important medical events that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above.

APD: All participants who received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Week 134

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No inferential statistics were planned for this endpoint.

End point values	2 milligrams (mg) Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib	Placebo to 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	388	378	189	191
Units: Percentage of Participants				
number (not applicable)	11.1	13.5	11.1	11.5

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Participants with Temporary Investigational Product Interruptions

End point title	Percentage of Participants with Temporary Investigational Product Interruptions <sup>[4]</sup>
-----------------	--

End point description:

Percentage of participants with temporary investigational product interruptions.

APD: All participants who received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Week 134

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No inferential statistics were planned for this endpoint.

End point values	2 milligrams (mg) Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib	Placebo to 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	388	378	189	191
Units: Percentage of Participants				
number (not applicable)	19.1	24.6	18.5	23.6

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Participants with Permanent Investigational Product Discontinuations

End point title	Percentage of Participants with Permanent Investigational Product Discontinuations <sup>[5]</sup>
-----------------	---

End point description:

Percentage of participants with permanent investigational product discontinuations.

APD: All participants who received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Week 134

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No inferential statistics were planned for this endpoint.

End point values	2 milligrams (mg) Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib	Placebo to 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	388	378	189	191
Units: Percentage of Participants				
number (not applicable)	5.2	5.8	4.2	5.8

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response

End point title	Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response
-----------------	--

End point description:

SRI-4 response defined as 1)greater than or equal to 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of  $\geq 0.3$  from baseline on a 0-3 visual analogue scale).

SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assesses disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe).

End point type	Secondary
----------------	-----------

End point timeframe:

Week 134

APD: All randomized participants who had SLEDAI-2K score of  $\geq 4$  at baseline.

End point values	2 milligrams (mg) Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib	Placebo to 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	388	379	129	131
Units: Percentage of participants				
number (not applicable)	0	0	0	0

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)

End point title	Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)
-----------------	---

End point description:

Percentage of participants achieving a LLDAS. The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K  $\leq 4$ , with no activity in major organ systems (CNS, vascular, renal, cardiorespiratory and constitutional); where "no activity" is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the "new feature" is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) PGA (scale 0-3),  $\leq 1$ ; (4) current prednisolone (or equivalent) dose  $\leq 7.5$  mg daily. APD: All participants who received at least one dose of study drug and had SLEDAI-2K score of  $\geq 4$  at baseline. Due to early termination of the study, this population consisted of participants who completed Week 48 treatment, or discontinued treatment prior to Week 48 (but not due to study termination).

End point type	Secondary
----------------	-----------

End point timeframe:

Week 48

End point values	2 milligrams (mg) Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib	Placebo to 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	289	261	98	100
Units: Percentage of participants				
number (not applicable)	29.8	33.0	19.4	26.0

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Prednisone Dose

End point title	Change from Baseline in Prednisone Dose
-----------------	---

End point description:

Change from baseline in prednisone dose.

APD: Due to early termination of the study, this population consisted of participants who completed Week 48 treatment, or discontinued treatment prior to Week 48 (but not due to study termination). Participants having values for this outcome were included.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline through Week 48

End point values	2 milligrams (mg) Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib	Placebo to 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	235	225	115	121
Units: milligrams (mg)				
least squares mean (standard error)	2.35 (± 0.305)	2.27 (± 0.316)	1.68 (± 0.426)	1.00 (± 0.419)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Annualized Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Flare Index Flare Rate

End point title	Annualized Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Flare Index Flare Rate
-----------------	--

End point description:

The SELENA-SLEDAI tool is a cumulative and weighted index used to assess disease activity across 24 different disease descriptors in patients with lupus. A patient's SELENA-SLEDAI total score is the sum of all marked lupus related descriptors (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, leukopenia). A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity. APD: Due to early termination of the study, this population consisted of participants who completed Week 48 treatment, or discontinued treatment prior to Week 48 (but not due to study termination). Participants having values for this outcome were included.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline through Week 48

End point values	2 milligrams (mg) Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib	Placebo to 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	289	261	136	143
Units: Index Flare Rate				
number (not applicable)	0.978	0.926	0.894	0.746

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants with Cutaneous Lupus Erythematosus

**Disease Area and Severity Index (CLASI) Total Activity Score  $\geq 10$  at Baseline with  $\geq 50\%$  Reduction in CLASI Total Activity Score**

End point title	Percentage of Participants with Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score $\geq 10$ at Baseline with $\geq 50\%$ Reduction in CLASI Total Activity Score
-----------------	---

## End point description:

The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations.

APD: All participants with CLASI Total Activity Score  $\geq 10$  at baseline. Due to early termination of the study, this population consisted of participants who completed Week 48 treatment, or discontinued treatment prior to Week 48 (but not due to study termination).

End point type	Secondary
----------------	-----------

## End point timeframe:

Week 48

End point values	2 milligrams (mg) Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib	Placebo to 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59	50	5	5
Units: Percentage of participants				
number (not applicable)	55.9	64.0	60.0	20.0

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Change from Baseline in Tender Joint Count**

End point title	Change from Baseline in Tender Joint Count
-----------------	--

## End point description:

The number of tender and painful joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as tender or not tender. LS mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K  $< 10$ ;  $\geq 10$ ), baseline corticosteroid dose ( $< 10$  mg/day;  $\geq 10$  mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.

End point type	Secondary
----------------	-----------

## End point timeframe:

Baseline through Week 48

APD: This population consisted of participants who completed Week 48 treatment, or discontinued treatment prior to Week 48 (but not due to study termination). Participants having values for this outcome were included.



End point values	2 milligrams (mg) Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib	Placebo to 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	230	217	113	119
Units: Tender joint count				
least squares mean (standard error)	-5.68 ( $\pm$ 0.281)	-5.85 ( $\pm$ 0.292)	-3.62 ( $\pm$ 0.383)	-3.73 ( $\pm$ 0.376)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Swollen Joint Count

End point title	Change from Baseline in Swollen Joint Count
End point description:	
<p>The number of swollen joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as swollen or not swollen. LS mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K &lt;10; <math>\geq</math>10), baseline corticosteroid dose (&lt;10 mg/day; <math>\geq</math>10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.</p> <p>APD: This population consisted of participants who completed Week 48 treatment, or discontinued treatment prior to Week 48 (but not due to study termination). Participants having values for this outcome were included.</p>	
End point type	Secondary
End point timeframe:	
Baseline trough Week 48	

End point values	2 milligrams (mg) Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib	Placebo to 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	230	217	113	119
Units: Swollen joint count				
least squares mean (standard error)	-4.03 ( $\pm$ 0.191)	-4.01 ( $\pm$ 0.196)	-3.19 ( $\pm$ 0.264)	-2.94 ( $\pm$ 0.257)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Total Score

End point title	Change from Baseline in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Total Score
End point description:	
The SLICC/ACR damage index is a validated instrument to assess damage, defined as irreversible	

impairment, continuously persistent for 6 months (ascertained by clinical assessment), occurring since the onset of lupus, and it is based on a weighted scoring system. This index records damage occurring in participants with SLE regardless of cause, with demonstrated content, face, criterion, and discriminant validity. A score of 0 indicates no damage. Total maximum score is 47 and increasing score indicates increasing disease severity.

APD: Due to early termination of the study, this population consisted of participants who completed Week 48 treatment, or discontinued treatment prior to Week 48 (but not due to study termination). Participants having values for this outcome were included.

End point type	Secondary
End point timeframe:	
Baseline through Week 48	

End point values	2 milligrams (mg) Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib	Placebo to 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	235	226	115	121
Units: Score on a scale				
arithmetic mean (standard deviation)	-0.03 ( $\pm$ 0.569)	-0.04 ( $\pm$ 0.544)	-0.04 ( $\pm$ 0.754)	-0.06 ( $\pm$ 0.505)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Worst Pain Numeric Rating Scale (NRS)

End point title	Change from Baseline in Worst Pain Numeric Rating Scale (NRS)
-----------------	---

End point description:

Change from baseline in Worst Pain NRS. It is assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". Overall severity of a patient's pain is indicated by selecting the number that best describes the worst level of pain during the past 7 days.

APD: Due to early termination of the study, this population consisted of participants who completed Week 48 treatment, or discontinued treatment prior to Week 48 (but not due to study termination). Participants having values for this outcome were included.

End point type	Secondary
End point timeframe:	
Baseline through Week 48	

End point values	2 milligrams (mg) Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib	Placebo to 4 mg Baricitinib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	220	207	111	118
Units: Score on a scale				
least squares mean (standard error)	-0.96 ( $\pm$ 0.167)	-1.23 ( $\pm$ 0.173)	-0.55 ( $\pm$ 0.222)	-0.83 ( $\pm$ 0.218)

## **Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline through Study Completion (Up to 134 Weeks)

Adverse event reporting additional description:

All participants who received at least one dose of study drug in Study JAIM and who did not discontinue from the study for the reason of Lost to Follow-up at the first postbaseline visit (Safety Population). Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

### Reporting groups

Reporting group title	2 mg Baricitinib
-----------------------	------------------

Reporting group description:

Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally QD.

Reporting group title	4 mg Baricitinib
-----------------------	------------------

Reporting group description:

Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally QD.

Reporting group title	Placebo to 2 mg Baricitinib
-----------------------	-----------------------------

Reporting group description:

Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 2 mg Baricitinib administered orally QD.

Reporting group title	Placebo to 4 mg Baricitinib
-----------------------	-----------------------------

Reporting group description:

Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 4 mg Baricitinib administered orally QD.

Serious adverse events	2 mg Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib
Total subjects affected by serious adverse events			
subjects affected / exposed	43 / 388 (11.08%)	53 / 378 (14.02%)	21 / 189 (11.11%)
number of deaths (all causes)	0	6	2
number of deaths resulting from adverse events	0	6	2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
colon adenoma			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
extranodal marginal zone b-cell lymphoma (malt type)			

alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
her2 positive breast cancer			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
invasive ductal breast carcinoma			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lung adenocarcinoma			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
metastases to liver			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
non-hodgkin's lymphoma			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
squamous cell carcinoma			
alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
squamous cell carcinoma of skin alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
uterine leiomyoma alternative dictionary used: MedDRA 24.0			
subjects affected / exposed <sup>[1]</sup>	0 / 361 (0.00%)	0 / 356 (0.00%)	1 / 181 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
accelerated hypertension alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
aortic stenosis alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
deep vein thrombosis alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
embolism arterial alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
jugular vein thrombosis alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
raynaud's phenomenon alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
cervical conisation alternative dictionary used: MedDRA 24.0			
subjects affected / exposed <sup>[2]</sup>	0 / 361 (0.00%)	0 / 356 (0.00%)	1 / 181 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholecystectomy alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
fasciotomy alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
abortion spontaneous alternative dictionary used: MedDRA 24.0			

subjects affected / exposed <sup>[3]</sup>	0 / 361 (0.00%)	1 / 356 (0.28%)	0 / 181 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
pain			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pyrexia			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
anaphylactic reaction			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
cervical dysplasia			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed <sup>[4]</sup>	2 / 361 (0.55%)	1 / 356 (0.28%)	0 / 181 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
endometriosis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed <sup>[5]</sup>	0 / 361 (0.00%)	1 / 356 (0.28%)	0 / 181 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			



acute respiratory distress syndrome			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
chronic obstructive pulmonary disease			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
dysphonia			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pleural effusion			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	2 / 388 (0.52%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pleurisy			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary embolism			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	2 / 378 (0.53%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary hypertension			
alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
acute psychosis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
depression suicidal			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hallucination			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
suicide attempt			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
biopsy			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
clostridium test positive			
alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
herpes simplex test positive alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
international normalised ratio increased alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
hand fracture alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ligament rupture alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
radius fracture alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
road traffic accident alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
upper limb fracture alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
wrist fracture alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
acute myocardial infarction alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
angina unstable alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
atrial fibrillation alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
atrial flutter alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cardiac failure congestive alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cardio-respiratory arrest alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
myocardial infarction alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pericardial effusion alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	2 / 388 (0.52%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
autoimmune neuropathy alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
central nervous system lupus alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebral infarction			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebral ischaemia			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cognitive disorder			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hypoaesthesia			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ischaemic stroke			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
seizure			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

syncope			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
immune thrombocytopenia			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
scleritis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
abdominal pain			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
colitis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diarrhoea			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
dysphagia			

alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
erosive oesophagitis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
small intestinal obstruction			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
vomiting			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	2 / 388 (0.52%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
bile duct stone			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholecystitis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholecystitis chronic			
alternative dictionary used: MedDRA 24.0			



subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholelithiasis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
immune-mediated hepatic disorder			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
rosacea			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
stevens-johnson syndrome			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
acute kidney injury			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
calculus urinary			
alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
glomerulonephritis membranous alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lupus nephritis alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
nephrolithiasis alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
proteinuria alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
renal impairment alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urinary incontinence alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Musculoskeletal and connective tissue disorders			
arthritis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
back pain			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
compartment syndrome			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
intervertebral disc protrusion			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
joint instability			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
musculoskeletal chest pain			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
osteoarthritis			
alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
osteonecrosis alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	3 / 189 (1.59%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pain in extremity alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
systemic lupus erythematosus alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	2 / 388 (0.52%)	5 / 378 (1.32%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 2	0 / 6	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tendon sheath disorder alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
acinetobacter sepsis alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
appendicitis alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
arthritis bacterial			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
atypical pneumonia			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bronchitis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
covid-19			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	7 / 378 (1.85%)	3 / 189 (1.59%)
occurrences causally related to treatment / all	0 / 0	1 / 7	2 / 3
deaths causally related to treatment / all	0 / 0	1 / 2	1 / 1
covid-19 pneumonia			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	5 / 388 (1.29%)	5 / 378 (1.32%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	1 / 5	1 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
cellulitis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	2 / 378 (0.53%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

cystitis				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
cytomegalovirus infection reactivation				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
endocarditis bacterial				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
escherichia pyelonephritis				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
escherichia urinary tract infection				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
gastroenteritis				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
gastroenteritis salmonella				
alternative dictionary used: MedDRA 24.0				

subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastroenteritis viral			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
herpes zoster			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
herpes zoster meningitis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
infection			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
influenza			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lower respiratory tract infection			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

lower respiratory tract infection bacterial			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
meningitis bacterial			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
osteomyelitis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	4 / 388 (1.03%)	1 / 378 (0.26%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 4	0 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia parainfluenzae viral			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia viral			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
post procedural infection			
alternative dictionary used: MedDRA 24.0			



subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary tuberculosis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pyelonephritis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pyelonephritis acute			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
renal abscess			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sinusitis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tubo-ovarian abscess			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed <sup>[6]</sup>	1 / 361 (0.28%)	0 / 356 (0.00%)	0 / 181 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

upper respiratory tract infection alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urinary tract infection alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	2 / 378 (0.53%)	1 / 189 (0.53%)
occurrences causally related to treatment / all	0 / 0	1 / 2	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
decreased appetite alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 388 (0.00%)	1 / 378 (0.26%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
dehydration alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hypomagnesaemia alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 388 (0.26%)	0 / 378 (0.00%)	0 / 189 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Placebo to 4 mg Baricitinib		
Total subjects affected by serious adverse events			
subjects affected / exposed	22 / 191 (11.52%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps) colon adenoma			

alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
extranodal marginal zone b-cell lymphoma (malt type)				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
her2 positive breast cancer				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
invasive ductal breast carcinoma				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
lung adenocarcinoma				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
metastases to liver				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
non-hodgkin's lymphoma				
alternative dictionary used: MedDRA 24.0				

subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
squamous cell carcinoma			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
squamous cell carcinoma of skin			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
uterine leiomyoma			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed <sup>[1]</sup>	0 / 176 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
accelerated hypertension			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
aortic stenosis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
deep vein thrombosis			
alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	1 / 191 (0.52%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
embolism arterial			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
jugular vein thrombosis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
raynaud's phenomenon			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 191 (0.52%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
cervical conisation			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed <sup>[2]</sup>	0 / 176 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
cholecystectomy			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 191 (0.52%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
fasciotomy			
alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal conditions			
abortion spontaneous			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed <sup>[3]</sup>	0 / 176 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
pain			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
pyrexia			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
anaphylactic reaction			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
cervical dysplasia			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed <sup>[4]</sup>	0 / 176 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
endometriosis			

alternative dictionary used: MedDRA 24.0				
subjects affected / exposed <sup>[5]</sup>	0 / 176 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory, thoracic and mediastinal disorders				
acute respiratory distress syndrome				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
chronic obstructive pulmonary disease				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
dysphonia				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pleural effusion				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pleurisy				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pulmonary embolism				
alternative dictionary used: MedDRA 24.0				

subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
pulmonary hypertension			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
acute psychosis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
depression suicidal			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
hallucination			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
suicide attempt			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
biopsy			
alternative dictionary used: MedDRA 24.0			



subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
clostridium test positive			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 191 (0.52%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
herpes simplex test positive			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
international normalised ratio increased			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
hand fracture			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ligament rupture			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
radius fracture			
alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
road traffic accident			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
upper limb fracture			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
wrist fracture			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
acute myocardial infarction			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 191 (0.52%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
angina unstable			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
atrial fibrillation			
alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
atrial flutter			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
cardiac failure congestive			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
cardio-respiratory arrest			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
myocardial infarction			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
pericardial effusion			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
autoimmune neuropathy			
alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
central nervous system lupus				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cerebral infarction				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cerebral ischaemia				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cognitive disorder				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
hypoaesthesia				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ischaemic stroke				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

seizure			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
syncope			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
immune thrombocytopenia			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
scleritis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
abdominal pain			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 191 (0.52%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
colitis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	1 / 191 (0.52%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
diarrhoea			

alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
dysphagia				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
erosive oesophagitis				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
small intestinal obstruction				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
vomiting				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatobiliary disorders				
bile duct stone				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	1 / 191 (0.52%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
cholecystitis				
alternative dictionary used: MedDRA 24.0				

subjects affected / exposed	1 / 191 (0.52%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
cholecystitis chronic			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
cholelithiasis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	2 / 191 (1.05%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
immune-mediated hepatic disorder			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
rosacea			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
stevens-johnson syndrome			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
acute kidney injury			
alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
calculus urinary				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
glomerulonephritis membranous				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
lupus nephritis				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
nephrolithiasis				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
proteinuria				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
renal impairment				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			



urinary incontinence alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 191 (0.00%) 0 / 0 0 / 0			
Musculoskeletal and connective tissue disorders				
arthritis alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 191 (1.05%) 0 / 2 0 / 0			
back pain alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 191 (0.52%) 0 / 1 0 / 0			
compartment syndrome alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 191 (0.00%) 0 / 0 0 / 0			
intervertebral disc protrusion alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 191 (0.00%) 0 / 0 0 / 0			
joint instability alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 191 (0.00%) 0 / 0 0 / 0			
musculoskeletal chest pain alternative dictionary used: MedDRA 24.0				

subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
osteoarthritis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
osteonecrosis			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
pain in extremity			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
systemic lupus erythematosus			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	3 / 191 (1.57%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
tendon sheath disorder			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	0 / 191 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
acinetobacter sepsis			
alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	1 / 191 (0.52%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
appendicitis				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
arthritis bacterial				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
atypical pneumonia				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
bronchitis				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
covid-19				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
covid-19 pneumonia				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	3 / 191 (1.57%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			

cellulitis				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
cystitis				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	1 / 191 (0.52%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
cytomegalovirus infection reactivation				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
endocarditis bacterial				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
escherichia pyelonephritis				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	3 / 191 (1.57%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
escherichia urinary tract infection				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
gastroenteritis				
alternative dictionary used: MedDRA 24.0				

subjects affected / exposed	1 / 191 (0.52%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
gastroenteritis salmonella				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
gastroenteritis viral				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
herpes zoster				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
herpes zoster meningitis				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
infection				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
influenza				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

lower respiratory tract infection alternative dictionary used: MedDRA 24.0 subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
lower respiratory tract infection bacterial alternative dictionary used: MedDRA 24.0 subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
meningitis bacterial alternative dictionary used: MedDRA 24.0 subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
osteomyelitis alternative dictionary used: MedDRA 24.0 subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pneumonia alternative dictionary used: MedDRA 24.0 subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pneumonia parainfluenzae viral alternative dictionary used: MedDRA 24.0 subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pneumonia viral alternative dictionary used: MedDRA 24.0				

subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
post procedural infection				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pulmonary tuberculosis				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
pyelonephritis				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	1 / 191 (0.52%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
pyelonephritis acute				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
renal abscess				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	1 / 191 (0.52%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
sinusitis				
alternative dictionary used: MedDRA 24.0				
subjects affected / exposed	0 / 191 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

tubo-ovarian abscess alternative dictionary used: MedDRA 24.0 subjects affected / exposed <sup>[6]</sup> occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 176 (0.00%) 0 / 0 0 / 0		
upper respiratory tract infection alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 191 (0.00%) 0 / 0 0 / 0		
urinary tract infection alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 191 (1.05%) 0 / 2 0 / 0		
Metabolism and nutrition disorders decreased appetite alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 191 (0.00%) 0 / 0 0 / 0		
dehydration alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 191 (0.00%) 0 / 0 0 / 0		
hypomagnesaemia alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 191 (0.00%) 0 / 0 0 / 0		

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.



Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	2 mg Baricitinib	4 mg Baricitinib	Placebo to 2 mg Baricitinib
Total subjects affected by non-serious adverse events			
subjects affected / exposed	54 / 388 (13.92%)	54 / 378 (14.29%)	35 / 189 (18.52%)
Infections and infestations			
covid-19			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	35 / 388 (9.02%)	32 / 378 (8.47%)	21 / 189 (11.11%)
occurrences (all)	35	33	22
urinary tract infection			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	20 / 388 (5.15%)	22 / 378 (5.82%)	17 / 189 (8.99%)
occurrences (all)	28	27	19

<b>Non-serious adverse events</b>	Placebo to 4 mg Baricitinib		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	29 / 191 (15.18%)		
Infections and infestations			
covid-19			
alternative dictionary used: MedDRA 24.0			
subjects affected / exposed	23 / 191 (12.04%)		
occurrences (all)	25		
urinary tract infection			
alternative dictionary used: MedDRA 24.0			

subjects affected / exposed	7 / 191 (3.66%)		
occurrences (all)	8		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
15 November 2019	- Removed secondary endpoints due to categorical nature not appropriate for long term study; - Information about study visits were updated; - Updated information about inclusion criteria, packaging and labelling, timing of doses, and blinding for better clarity; - Updated text related to temporary interruption of investigational product, efficacy and safety analyses, adverse events for better clarity.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

This study was terminated due to insufficient evidence to support a positive benefit: risk profile. Safety findings were consistent with previously published OLUMIANT data.

Notes: